TauRx Therapeutics
Privately held: no public share price · New Zealand / United Kingdom
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Tau aggregation; AcetylcholineSmall molecule | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
29 July 2024Filing acceptedHydromethylthionine mesylateMHRA accepted the UK marketing authorisation application for HMTM
UK, MHRA · Source ↗
Financial reports
No financial reports recorded.